CA2999747A1 - Methods for treating heart failure using glucagon receptor antagonistic antibodies - Google Patents
Methods for treating heart failure using glucagon receptor antagonistic antibodies Download PDFInfo
- Publication number
- CA2999747A1 CA2999747A1 CA2999747A CA2999747A CA2999747A1 CA 2999747 A1 CA2999747 A1 CA 2999747A1 CA 2999747 A CA2999747 A CA 2999747A CA 2999747 A CA2999747 A CA 2999747A CA 2999747 A1 CA2999747 A1 CA 2999747A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- seq
- subject
- amino acid
- antigen binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562214449P | 2015-09-04 | 2015-09-04 | |
| US62/214,449 | 2015-09-04 | ||
| US201562259061P | 2015-11-24 | 2015-11-24 | |
| US62/259,061 | 2015-11-24 | ||
| PCT/US2016/050183 WO2017040986A1 (en) | 2015-09-04 | 2016-09-02 | Methods for treating heart failure using glucagon receptor antagonistic antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2999747A1 true CA2999747A1 (en) | 2017-03-09 |
Family
ID=58188491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2999747A Pending CA2999747A1 (en) | 2015-09-04 | 2016-09-02 | Methods for treating heart failure using glucagon receptor antagonistic antibodies |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10765737B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3344279B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6890340B6 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108348582B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016318097B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2999747A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017040986A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7005638B2 (ja) | 2017-01-27 | 2022-02-04 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | グルカゴン受容体結合タンパク質及びその使用方法 |
| EP3829636A1 (en) | 2018-07-27 | 2021-06-09 | NGM Biopharmaceuticals, Inc. | Use of glucagon receptor antagonists with immunotherapeutic agent |
| JP7840511B2 (ja) | 2019-02-01 | 2026-04-06 | 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 | 抗クローディン18抗体及びそれらの使用の方法 |
| CN118393150B (zh) * | 2024-06-27 | 2024-09-13 | 潍坊市润生畜禽良种有限公司 | 一种优化gcgr卵黄抗体制备的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030103983A1 (en) | 2002-05-09 | 2003-06-05 | Pressler Milton Lethan | Ace inhibitor-vasopressin antagonist combinations |
| WO2006005469A2 (en) | 2004-07-15 | 2006-01-19 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr) |
| CL2007002668A1 (es) * | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| US9034883B2 (en) * | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US8771696B2 (en) | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
-
2016
- 2016-09-02 CA CA2999747A patent/CA2999747A1/en active Pending
- 2016-09-02 WO PCT/US2016/050183 patent/WO2017040986A1/en not_active Ceased
- 2016-09-02 AU AU2016318097A patent/AU2016318097B2/en not_active Ceased
- 2016-09-02 EP EP16843103.9A patent/EP3344279B1/en active Active
- 2016-09-02 JP JP2018511277A patent/JP6890340B6/ja active Active
- 2016-09-02 CN CN201680061804.XA patent/CN108348582B/zh active Active
- 2016-09-02 US US15/757,352 patent/US10765737B2/en active Active
-
2020
- 2020-07-28 US US16/941,290 patent/US11446376B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200353079A1 (en) | 2020-11-12 |
| US11446376B2 (en) | 2022-09-20 |
| CN108348582B (zh) | 2023-04-14 |
| JP2018528210A (ja) | 2018-09-27 |
| AU2016318097B2 (en) | 2023-04-20 |
| AU2016318097A1 (en) | 2018-04-12 |
| WO2017040986A1 (en) | 2017-03-09 |
| EP3344279A1 (en) | 2018-07-11 |
| US20180256713A1 (en) | 2018-09-13 |
| US10765737B2 (en) | 2020-09-08 |
| CN108348582A (zh) | 2018-07-31 |
| JP6890340B2 (ja) | 2021-06-18 |
| JP6890340B6 (ja) | 2021-07-14 |
| EP3344279A4 (en) | 2019-03-27 |
| EP3344279B1 (en) | 2020-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11446376B2 (en) | Methods for treating heart failure using glucagon receptor antagonistic antibodies | |
| US20230126271A1 (en) | Degrader-antibody conjugates and methods of using same | |
| EP2951205B1 (en) | Anti-activin-a compounds for the treatment of ovarian cancer | |
| US11447555B2 (en) | Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies | |
| KR20110074898A (ko) | 염증을 치료하는 방법 | |
| JP2011526244A (ja) | 炎症の処置方法 | |
| RS59354B1 (sr) | Postupci lečenja nosne polipoze davanjem il-4r antagonista | |
| CN117222663A (zh) | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 | |
| TW202317175A (zh) | 用於重量管理及相關代謝病症之療法 | |
| AU2020319899A1 (en) | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics | |
| CA2980765A1 (en) | Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies | |
| CA3041325A1 (en) | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody | |
| US20230372518A1 (en) | Antimitotic tetrapeptide-antibody conjugates and methods of using same | |
| WO2022109302A1 (en) | Anti-galectin-9 antibodies and therapeutic uses thereof | |
| JP2023539107A (ja) | アクチビンaアンタゴニストによる心機能障害及びcovid-19の予防及び治療方法 | |
| US20240166759A1 (en) | Combinations comprising anti-tm4sf1 antibodies and immunotherapeutic agents and methods of using the same | |
| WO2026101890A1 (en) | Combinations of anti-il-27 antibodies with toripalimab and bevacizumab | |
| CN115279393A (zh) | 以介白素24或介白素20拮抗剂治疗组织纤维化和/或损伤和/或器官衰竭 | |
| CN116490520A (zh) | 用于covid-19肺炎的托珠单抗和瑞德西韦组合疗法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210823 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241105 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241224 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241224 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251222 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260220 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260223 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260421 |